University of North Carolina at Chapel Hill (SCD subjects only)
Welcome,         Profile    Billing    Logout  
 0 Trials 
1 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Carden, Marcus
HIBISCUS 3, NCT05953584: A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

Recruiting
2
46
RoW
Etavopivat, Hydroxyurea
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
07/25
05/26

Download Options